AI Article Synopsis

  • The study investigates the role of circulating tumor cells (CTCs) in managing nasopharyngeal carcinoma (NPC) and emphasizes their potential for personalized treatment.
  • It analyzed 141 patients with locally advanced NPC, categorizing CTCs into different epithelial-mesenchymal transition (EMT) subtypes before and after treatment.
  • Findings reveal that higher counts of mesenchymal CTCs and overall CTCs are associated with worse prognosis and correlate significantly with various clinical features and overall survival rates.

Article Abstract

Background: Advancements in nasopharyngeal carcinoma (NPC) treatment have led to a focus on personalized treatment. Circulating tumor cells (CTCs) are important for liquid biopsies and personalized treatment but are not being fully utilized. This study examined how pre- and post-treatment CTC counts, EMT subtypes, clinical characteristics, and patient prognosis are related in order to support the use of liquid biopsy in managing NPC.

Methods: This retrospective study included 141 patients with locally advanced NPC. All patients underwent CanPatrol™ CTC detection pre- and post-treatment and were categorized into EMT subtypes: epithelial type, mixed type, and mesenchymal type. This study analyzed CTC enumeration, EMT subtypes, and their associations with clinical characteristics and survival outcomes.

Results: The results indicated a positive correlation between the pre-treatment detection rate of CTCs and N stage (P < 0.01), alongside a positive correlation with the TNM clinical stage (P = 0.02). Additionally, the detection rate of mesenchymal CTCs post-treatment is positively associated with the N stage (P = 0.02). The enumeration of CTCs pre- and post-treatment is negatively correlated with prognosis and has statistical significance. Additionally, an investigation into the EMT subtypes of CTCs revealed a significant association between the presence of mesenchymal CTCs pre- and post-treatment and decreased overall survival (OS) (P < 0.05). Furthermore, T stage, N stage, TNM clinical stage, and Epstein-Barr virus (EBV) DNA were also significantly correlated with OS.

Conclusion: The study found that mesenchymal CTCs pre- and post-treatment, as well as the number of CTCs, were linked to a poor prognosis.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00405-024-08714-wDOI Listing

Publication Analysis

Top Keywords

emt subtypes
12
circulating tumor
8
tumor cells
8
locally advanced
8
nasopharyngeal carcinoma
8
personalized treatment
8
pre- post-treatment
8
clinical characteristics
8
cells valuable
4
valuable indicator
4

Similar Publications

Bladder cancer (BLCA) genomic profiling has identified molecular subtypes with distinct clinical characteristics and variable sensitivities to frontline therapy. BLCAs can be categorized into luminal or basal subtypes based on their gene expression. We comprehensively characterized nine human BLCA cell lines (UC3, UC6, UC9, UC13, UC14, T24, SCaBER, RT4V6 and RT112) into molecular subtypes using orthotopic xenograft models.

View Article and Find Full Text PDF

Triple-negative breast cancer (TNBC) remains a challenging subtype due to its aggressive nature and limited treatment options. This study investigated the potential synergistic effects of Korean mistletoe lectin ( L. agglutinin, VCA) and cisplatin on MDA-MB-231 TNBC cells using both 2D and 3D culture models.

View Article and Find Full Text PDF

Lung adenocarcinoma (LUAD) is the most common histological subtype of lung cancer, characterized by a high incidence in late stages, high mortality rate, and poor prognosis. Src Homology 2 Domain Containing Protein 5 (SH2D5) is a mammalian-specific, uncharacterized scaffolding protein, and its role in LUAD remains unclear. In the present study, we investigated the function and potential mechanisms of SH2D5 in the progression of LUAD.

View Article and Find Full Text PDF

Triple-negative breast cancer (TNBC) represents an aggressive form of breast cancer with few available therapeutic options. Chemotherapy, particularly with drugs like doxorubicin (DOX), remains the cornerstone of treatment for this challenging subtype. However, the clinical utility of DOX is hampered by adverse effects that escalate with higher doses and drug resistance, underscoring the need for alternative therapies.

View Article and Find Full Text PDF

Triple-negative breast cancer (TNBC) is a subtype known for its aggressive nature, high rates of recurrence, and treatment resistance, largely attributed to the presence of breast cancer stem cells (BCSCs). Traditional therapies often struggle to eliminate BCSCs, which contributes to tumor recurrence. One promising strategy for addressing this challenge is targeting the Notch signaling pathway, which plays a critical role in the self-renewal and maintenance of BCSCs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!